HYULIM A-TECH Co., Ltd. Share Price

Equities

A078590

KR7078590007

Auto, Truck & Motorcycle Parts

End-of-day quote Korea S.E. 23:00:00 29/04/2024 BST 5-day change 1st Jan Change
837 KRW -1.76% Intraday chart for HYULIM A-TECH Co., Ltd. -1.30% -30.25%

Financials

Sales 2019 64.6B 46.64M 3.74B Sales 2020 61.41B 44.33M 3.55B Capitalization 404B 292M 23.36B
Net income 2019 -6.05B -4.37M -350M Net income 2020 -180B -130M -10.39B EV / Sales 2019 1.21 x
Net cash position 2019 7.67B 5.54M 444M Net Debt 2020 4B 2.89M 231M EV / Sales 2020 6.64 x
P/E ratio 2019
-13.5 x
P/E ratio 2020
-2.09 x
Employees 94
Yield 2019 *
-
Yield 2020
-
Free-Float 52.94%
More Fundamentals * Assessed data
Dynamic Chart
DIAC Co., Ltd. acquired Automotive division of CANARIABIO M Inc. CI
Diac to Raise $7.8 Million via Share Issuance MT
DIAC Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Hyulim ROBOT Co.,Ltd. CI
OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer CI
OncoQuest Pharmaceuticals Inc. completed the spin-off of OQP BIO Inc. CI
OncoQuest Pharmaceuticals Inc. completed the spin-off of Dual Moolsan Holdings Co., Ltd. CI
Quest PharmaTech Inc. Announces Two Presentations by Oncoquest Pharmaceuticals, Inc. At the 2021 Annual Meeting of the American Association of Clinical Oncologists CI
The Board of Directors of OncoQuest Pharmaceuticals Inc. announced to spin off Manufacturing Management Division. CI
The Board of Directors of OncoQuest Pharmaceuticals Inc. announced to spin-off biotechnology division. CI
OncoQuest Pharmaceuticals Inc.(KOSDAQ:A078590) dropped from S&P Global BMI Index CI
OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer CI
OncoQuest Pharmaceuticals, Inc. Appoints Dr. Sunil Gupta as Chief Medical Officer CI
DUAL Industrial Co., Ltd's Equity Buyback announced on March 25, 2020, has expired. CI
OncoQuest Pharmaceuticals Inc.(KOSDAQ:A078590) added to S&P Global BMI Index CI
DUAL Industrial Co., Ltd. announced that it has received KRW 20 billion in funding CI
More news
1 day-1.76%
1 week-1.30%
Current month-11.33%
1 month-11.33%
3 months-19.71%
6 months-12.81%
Current year-30.25%
More quotes
1 week
796.00
Extreme 796
859.00
1 month
796.00
Extreme 796
988.00
Current year
796.00
Extreme 796
1 695.00
1 year
796.00
Extreme 796
2 975.00
3 years
796.00
Extreme 796
2 975.00
5 years
796.00
Extreme 796
18 425.00
10 years
796.00
Extreme 796
18 425.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 04/03/19
Chief Tech/Sci/R&D Officer - 08/11/20
Director/Board Member 59 -
Members of the board TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member 62 -
More insiders
Date Price Change Volume
30/04/24 837 -1.76% 302,409
29/04/24 852 +1.07% 228,165
26/04/24 843 -0.35% 139,664
25/04/24 846 -0.24% 225,774
24/04/24 848 +0.36% 167,968

End-of-day quote Korea S.E., April 29, 2024

More quotes
Hyulim A-Tech Co Ltd, formerly Diac Co Ltd, is a Korea-based company mainly engaged in the manufacture and sale of automobile parts. The Company is engaged in the manufacture and sale of interior materials including carpets and trunk trims, as well as exterior materials such as wheel guards and under covers. Additionally, the Company is engaged in the manufacture of automobiles and trailers.
More about the company
  1. Stock Market
  2. Equities
  3. A078590 Stock